Medical and Prescription Drug Dashboard - Active Employees

Previous Period: Apr 2022 - Mar 2023 (Paid)
Current Period: Apr 2023 - Mar 2024 (Paid)

1. Quality Metrics

![Percentage Chart]

- HEDIS IET AOD Tx
  - Previous: 33%
  - Current: 33%
  - Trend: 0%

- HEDIS AMM
  - Previous: 82%
  - Current: 83%
  - Trend: 1%

- HEDIS SPD Statin Therapy w/ Diabetes Rate (DM)
  - Previous: 66%
  - Current: 66%
  - Trend: 0%

- HEDIS SPC Statin Therapy w/ ASCVD Total Rate (DM)
  - Previous: 82%
  - Current: 80%
  - Trend: -2%

2. High Cost Claimants

![Bar Chart]

- Patients: 1,025 → 1,020 (0.5%)
- Patients per 1,000: 11.4 → 11.1 (-2.2%)
- Payments (in Millions): $207M → $214M (3.7%)
- Payments per Patient: 201,838 → 210,284 (4.2%)

3. Well Care and Preventive Visits

<table>
<thead>
<tr>
<th>Visits per 1,000</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well Baby</td>
<td>5712.9</td>
<td>5572.3</td>
<td>-2.5%</td>
</tr>
<tr>
<td>Well Child</td>
<td>985.5</td>
<td>839.4</td>
<td>-14.8%</td>
</tr>
<tr>
<td>Prevent Adult</td>
<td>518.0</td>
<td>535.0</td>
<td>3.3%</td>
</tr>
</tbody>
</table>

4. Medical Eligibility

<table>
<thead>
<tr>
<th>Average Employees</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>39,257.2</td>
<td>40,344.4</td>
<td>2.8%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Average Members</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>90,070.3</td>
<td>91,685.1</td>
<td>1.8%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Family Size</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3</td>
<td>2.3</td>
<td>0.0%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Member Age</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>32.7</td>
<td>32.7</td>
<td>0.0%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Members % Male</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>46.0%</td>
<td>46.0%</td>
<td>0.0%</td>
<td></td>
</tr>
</tbody>
</table>

5. Risk Score

<table>
<thead>
<tr>
<th>Member Risk Score</th>
<th>Previous</th>
<th>Current</th>
</tr>
</thead>
<tbody>
<tr>
<td>143.5</td>
<td>147.4</td>
<td></td>
</tr>
</tbody>
</table>

6. Price and Use

<table>
<thead>
<tr>
<th>Inpatient Allowed per Admit</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>32,728</td>
<td>$32,513</td>
<td>-0.7%</td>
<td>$27,670</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Admits per 1000</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>55.8</td>
<td>51.3</td>
<td>-8.1%</td>
<td>47.6</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outpatient Allowed per Service</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>5150</td>
<td>$160</td>
<td>-6.3%</td>
<td>$140</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ER Visits per 1000</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>278.6</td>
<td>267.0</td>
<td>-4.2%</td>
<td>225.2</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-Specialty Rx Allowed per Days Suppy</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2</td>
<td>$3</td>
<td>11.6%</td>
<td>n/a</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specialty Rx Allowed per Days Suppy</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>$121</td>
<td>$129</td>
<td>6.4%</td>
<td>n/a</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Days Supply PMPY</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>447</td>
<td>426</td>
<td>2.0%</td>
<td>n/a</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specialty Rx All Allowed per Days Suppy</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>8</td>
<td>10.1%</td>
<td>n/a</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>All RX Allowed per Days Suppy</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4</td>
<td>$5</td>
<td>13.0%</td>
<td>n/a</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Days Supply PMPY</th>
<th>Previous</th>
<th>Current</th>
<th>Trend</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>425</td>
<td>434</td>
<td>2.1%</td>
<td>33%</td>
<td></td>
</tr>
</tbody>
</table>

7. Cost Sharing

![Graph]

- IP Price
- IP Use
- LOS
- OP Price
- OP Use
- ER Use
- Rx Price
- Rx Use

- Out of Pocket as a % of Allowed Amount
  - Medical
    - Previous: 4.7%
    - Current: 4.9%
  - Rx
    - Previous: 5.9%
    - Current: 5.0%
  - Total
    - Previous: 4.9%
    - Current: 4.9%

Page 3 of 8
### 8. Top Medical Conditions (by cost)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Allowed Amount Med</th>
<th>Patients Med</th>
<th>Med Allowed per Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Prevent/Admin Hlth Encounters</td>
<td>$36,930,177</td>
<td>64,799</td>
<td>$570</td>
</tr>
<tr>
<td>2 Signs/Symptoms/Oth Cond, NEC</td>
<td>$27,535,281</td>
<td>25,601</td>
<td>$1,076</td>
</tr>
<tr>
<td>3 Pregnancy without Delivery</td>
<td>$26,332,875</td>
<td>2,686</td>
<td>$9,800</td>
</tr>
<tr>
<td>4 Chemotherapy Encounters</td>
<td>$20,882,032</td>
<td>216</td>
<td>$96,766</td>
</tr>
<tr>
<td>5 Newborns, w/o Complication</td>
<td>$18,283,323</td>
<td>1,363</td>
<td>$13,414</td>
</tr>
<tr>
<td>6 Arthropathies/Join Dist NEC</td>
<td>$16,488,588</td>
<td>17,785</td>
<td>$927</td>
</tr>
<tr>
<td>7 Gastroint Dist, NEC</td>
<td>$15,141,831</td>
<td>10,022</td>
<td>$1,511</td>
</tr>
<tr>
<td>8 Osteoarthrits</td>
<td>$14,547,563</td>
<td>5,547</td>
<td>$2,623</td>
</tr>
<tr>
<td>9 Spinal/Back Dist, Low Back</td>
<td>$14,438,551</td>
<td>9,357</td>
<td>$1,543</td>
</tr>
<tr>
<td>10 Cancer - Breast</td>
<td>$13,109,628</td>
<td>631</td>
<td>$20,776</td>
</tr>
</tbody>
</table>

### 9. Screening Rates

- **% with Annual Screenings**
  - Colon Cancer: 61%
  - Breast Cancer: 60%
  - Cervical Cancer: 58%
  - Cholesterol: 58%

### 10. Chronic Condition Prevalence

- **Patients per 1000**
  - Low Back Pain: 91 (benchmark: 105)
  - Depression: 54 (benchmark: 54)
  - Osteoarthritis: 48 (benchmark: 48)
  - Hypertension: 66 (benchmark: 66)
  - Diabetes: 62 (benchmark: 62)
  - Coronary Artery Disease: 80 (benchmark: 90)
  - Asthma: 37 (benchmark: 37)

### 11. Prescription Drug Metrics

- ** Allowed Amount Rx | Patients Rx | Rx Allowed per Patient |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Immunosuppressants, NEC</td>
<td>$51,083,690</td>
<td>1,170</td>
</tr>
<tr>
<td>2 Antidiabetic Agents, Misc</td>
<td>$28,160,644</td>
<td>6,919</td>
</tr>
<tr>
<td>3 Molecular Targeted Therapy</td>
<td>$11,186,440</td>
<td>194</td>
</tr>
<tr>
<td>4 CNS Agents, Misc.</td>
<td>$8,181,538</td>
<td>2,358</td>
</tr>
<tr>
<td>5 Antidiabetic Ag, SGLT Inhibir</td>
<td>$7,350,727</td>
<td>1,653</td>
</tr>
<tr>
<td>6 Stimulant, Amphetamine Type</td>
<td>$7,170,284</td>
<td>6,535</td>
</tr>
<tr>
<td>7 Misc Therapeutic Agents, NEC</td>
<td>$6,953,393</td>
<td>1,915</td>
</tr>
<tr>
<td>8 Antivirals, NEC</td>
<td>$6,483,014</td>
<td>6,471</td>
</tr>
<tr>
<td>9 Antidiabetic Agents, Insulins</td>
<td>$5,777,929</td>
<td>1,385</td>
</tr>
<tr>
<td>10 Adrenals &amp; Comb, NEC</td>
<td>$5,346,213</td>
<td>17,245</td>
</tr>
</tbody>
</table>

**Cholesterol**

- **Previous**: 52%
- **Current**: 52%
- **Benchmark**: 52%

**Cervical Cancer**

- **Previous**: 27%
- **Current**: 31%
- **Benchmark**: 37%

**Breast Cancer**

- **Previous**: 16%
- **Current**: 16%
- **Benchmark**: 16%

**Low Back Pain**

- **Previous**: 82%
- **Current**: 82%
- **Benchmark**: 82%